This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Nakahara Y, Hosomi Y, Shibuya M, Mitsufuji H, Katagiri M, Naoki K, etal. Multicenter study of Zolendronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017. MolClinOncol. 2019 Oct 1;11(4):349–53.NakaharaYHosomiYShibuyaMMitsufujiHKatagiriMNaokiKMulticenter study of Zolendronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 10172019Oct111434953Search in Google Scholar
Landi L, D’Incà F, Gelibter A, Chiari R, Grossi F, Delmonte A, etal. Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. J Immunother Cancer. 2019 Dec;7(1):1–9.LandiLD’IncàFGelibterAChiariRGrossiFDelmonteABone metastases and immunotherapy in patients with advanced non-small-cell lung cancer2019Dec7119Search in Google Scholar
Clézardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, et al. Bone metastasis: Mechanisms, therapies, and biomarkers. Physiol Rev. 2021 Jul 1;101(3):797–855.ClézardinPColemanRPuppoMOttewellPBonnelyeEPaychaFBone metastasis: Mechanisms, therapies, and biomarkers2021Jul11013797855Search in Google Scholar
Tam AH, Schepers AJ, Qin A, Nachar VR. Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non–Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases. Ann Pharmacother. 2021 Jun;55(6):697–704.TamAHSchepersAJQinANacharVRImpact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non–Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases2021Jun556697704Search in Google Scholar
Zhang G, Cheng R, Zhang Z, Jiang T, Ren S, Ma Z, et.al. Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases. Sci Rep. 2017 Feb 17;7(1):1–7.ZhangGChengRZhangZJiangTRenSMaZBisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases2017Feb177117Search in Google Scholar
Belwal CK, Patel J. Solvent-free synthesis for imidazole-1-yl-acetic acid hydrochloride: an intermediate for Zolendronic acid. Asian J Green Chem. 2019;3(4):483–91.BelwalCKPatelJSolvent-free synthesis for imidazole-1-yl-acetic acid hydrochloride: an intermediate for Zolendronic acid20193448391Search in Google Scholar
Zoledronic acid. In: In Depth Answers [Internet database]. Greenwood Village (CO): IBM Corporation; 2022 [cited 2022 Aug 21]. Available from: www.micromedexsolutions.comZoledronic acidIn:Greenwood Village (CO)IBM Corporation2022[cited 2022 Aug 21]. Available from: www.micromedexsolutions.comSearch in Google Scholar
Noronha V, Pinninti R, Patil VM, Joshi A, Prabhash K. Lung cancer in the Indian subcontinent. South Asian J Cancer. 2016;5(03):95–103.NoronhaVPinnintiRPatilVMJoshiAPrabhashKLung cancer in the Indian subcontinent201650395103Search in Google Scholar
Malik PS, Raina V. Lung cancer: prevalent trends & emerging concepts. Indian J Med Res. 2015;141(1):5.MalikPSRainaVLung cancer: prevalent trends & emerging concepts201514115Search in Google Scholar
Zhou Y, Yu QF, Peng AF, Tong WL, Liu JM, Liu ZL. The risk factors of bone metastases in patients with lung cancer. Sci Rep. 2017;7(1):1–6.ZhouYYuQFPengAFTongWLLiuJMLiuZLThe risk factors of bone metastases in patients with lung cancer20177116Search in Google Scholar
Tassone P, Tagliaferri P, Viscomi C, Palmieri C, Caraglia M, D’alessandro A, et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br. J. Cancer. 2003;88(12):1971–8.TassonePTagliaferriPViscomiCPalmieriCCaragliaMD’alessandroAZoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro2003881219718Search in Google Scholar
Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases. Clin. Breast Cancer. 2012;12(4):247–58.XieJDienerMSorgRWuEQNamjoshiMCost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases201212424758Search in Google Scholar